Regulatory Beat: Washington Seeks New Therapies to Combat Bioterrorism, Cancer, Obesity - BioShield legislation and HHS regulatory changes provide new opportunities and support for biotech manufacture

ADVERTISEMENT

Regulatory Beat: Washington Seeks New Therapies to Combat Bioterrorism, Cancer, Obesity
BioShield legislation and HHS regulatory changes provide new opportunities and support for biotech manufacturers.


BioPharm International



Jill Wechsler
Despite escalating criticism of exorbitant prices for new drugs and biotech therapies, coupled with demands for access to cheap imports, policymakers continue to support the development of new biomedical products, especially those that combat life-threatening diseases and terrorist threats. The need to maintain incentives for biotech innovation, while addressing such hot-button issues such as follow-on generics and Medicare reimbursement, will challenge Rep. James Greenwood (R-Pa) as he becomes the head of BIO (see "Greenwood to Lead BIO").

Promoting CountermeasuresOne main goal of the Bush administration is to encourage private sector development of new vaccines and treatments to protect against biological warfare. After almost two years of disputes and delay, Congress approved Project BioShield in July, and President Bush signed the bill soon after. The legislation provides $5.6 billion over 10 years to stockpile vaccines and other countermeasures to biological and chemical warfare. The bill also permits the National Institutes of Health (NIH) to expedite approval of grants for countermeasure R&D, gives FDA authority to allow emergency use of not-yet-approved treatments, and encourages speedy FDA approval of these products. FDA is urging manufacturers with investigational new drugs (INDs) that may be bioterror countermeasures to come in for "pre-pre-IND" meetings to ensure that researchers conduct necessary analyses in early studies.




While the bill was delayed for months due to a dispute over budget control, officials at the departments of Health and Human Services (HHS) and Homeland Security (DHS) have been negotiating preliminary agreements with manufacturers for new countermeasures. One major project will provide $700 million to purchase 75 million doses of an improved anthrax vaccine made with recombinant technology, high-volume fermentation, and modern protein purification methods. A related initiative seeks to acquire antitoxin treatments for inhalation anthrax disease, including monoclonal anti-PA antibodies, polyclonal anti-anthrax antibodies, and human immunoglobulin. HHS also is seeking antidotes and other products to treat and protect against smallpox, botulism, plague, Ebola virus, and radiation from "dirty bombs."

Missing ProtectionsAlthough the legislation offers incentives for manufacturers developing these products, it has a serious shortcoming from industry's perspective: it fails to include liability protections for companies if bioterror vaccines or drugs cause adverse events. And because the federal government is the main customer for countermeasures, manufacturers expressed concerns about regulated prices and lower return on investment in this field. Big pharma companies are generally delaying major investment in bioterror contracts, leaving the field to smaller biotech manufacturers.

Legislators and industry are discussing a BioShield II bill to provide liability protection for manufacturers and additional incentives for product development. Sens. Joseph Lieberman (D-Conn) and Orrin Hatch (R-Utah) expect hearings this fall on new tax and patent provisions, such as a proposal to offer companies that develop countermeasures "wild card" patent extensions — the opportunity to apply a two-year patent extension to an unrelated patent. Lieberman also suggested adding incentives for developing new antibiotics, and other critical treatment categories may be included in the next bill.

Development of counter-terrorism treatments also may become a campaign issue. In June, Democratic presidential nominee Sen. John Kerry (D-Mass) called for building a "medical arsenal of democracy" by speeding the transition from basic discovery to clinical trials for new drugs and vaccines. Kerry has accused the Bush administration of failing to address weaknesses in the nation's bioterrorism defenses, but his proposals for responding to biological threats appear similar to the president's.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here